Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | NSD2 | O96028 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | CASP6 | P55212 | 1/20 | 0.35 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7124498 | 0.82 | BRD4 (0.38) | SRCTDP1L3MBTL1 | |
| SCHEMBL31304872 | 0.79 | MAPT (0.45) | KDM4EGAAHPGDHSD17B10ALDH1A1 | |
| SCHEMBL31304912 | 0.78 | KEAP1 (0.37) | KDM4EGAAHPGDHSD17B10NOTUM | |
| SCHEMBL31304911 | 0.78 | KEAP1 (0.37) | KDM4EGAAHPGDHSD17B10NOTUM | |
| SCHEMBL24191749 | 0.77 | KDM4E (0.52) | KDM4EGAAHSD17B10ALDH1A1POLB | |
| SCHEMBL31304926 | 0.76 | KEAP1 (0.36) | KDM4EGAAHPGDHSD17B10ALDH1A1 | |
| SCHEMBL593547 | 0.74 | NOTUM (0.57) | KDM4EGAAHPGDHSD17B10CYP19A1 | |
| SCHEMBL6319608 | 0.73 | SRC (0.49) | KDM4EGAAHPGDHSD17B10SRC | |
| SCHEMBL6329045 | 0.72 | HRH4 (0.46) | L3MBTL1 | |
| SCHEMBL21746 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739694-A2 | MACROCYCLIC COMPOUNDS AND USE AS TYK2 INHIBITORS | Blossomhill Therapeutics, Inc. (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20250074920-A1 | MACROCYCLIC COMPOUNDS AND USE AS KINASE INHIBITORS | BLOSSOMHILL THERAPEUTICS INC (US) | 2025-03-06 | — | — | US | disclosed |
| WO-2025010294-A2 | MACROCYCLIC COMPOUNDS AND USE AS TYK2 INHIBITORS | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2025-01-09 | — | — | WO | disclosed |
| EP-4460498-A1 | MACROCYCLIC COMPOUNDS AND USE AS KINASE INHIBITORS | Blossomhill Therapeutics, Inc. (US) | 2024-11-13 | — | — | EP | disclosed |
| US-20230257396-A1 | MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS INC (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230257396-A1 | MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS INC (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230257396-A1 | MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS INC (US) | 2023-08-17 | — | — | US | disclosed |
| WO-2023133375-A1 | MACROCYCLIC COMPOUNDS AND USE AS KINASE INHIBITORS | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023133375-A1 | MACROCYCLIC COMPOUNDS AND USE AS KINASE INHIBITORS | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| CN-116171279-A | Macrocyclic compounds and uses thereof | 荣山医药股份有限公司 | 2023-05-26 | — | — | CN | disclosed |
| WO-2003015608-A2 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | SUGEN, INC. (US) | 2003-02-27 | — | — | WO | disclosed |
| US-20020187978-A1 | 4-Heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors | SUGEN, INC. | 2002-12-12 | — | — | US | disclosed |
| WO-2002096361-A2 | 5-ARALKYLSULFONYL-3- (PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | SUGEN, INC. (US) | 2002-12-05 | — | — | WO | disclosed |
| EP-1255752-A2 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | Sugen, Inc. (US) | 2002-11-13 | — | — | EP | disclosed |
| US-20020156292-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PHARMACIA & UPJOHN COMPANY LLC | 2002-10-24 | — | — | US | disclosed |
| WO-2002081466-A1 | PRODRUGS OF 3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES | SUGEN, INC. (US) | 2002-10-17 | — | — | WO | disclosed |
| EP-1233943-A2 | IONIZABLE INDOLINONE DERIVATIVES AND THEIR USE AS PTK LIGANDS | Sugen, Inc. (US) | 2002-08-28 | — | — | EP | disclosed |
| WO-2002055517-A2 | 4-(HETERO)ARYL SUBSTITUTED INDOLINONES | CUI JINGRONG (US) | 2002-07-18 | — | — | WO | disclosed |
| WO-2001060814-A2 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 2001-08-23 | — | — | WO | disclosed |
| WO-2001037820-A2 | IONIZABLE INDOLINONE DERIVATIVES AND THEIR USE AS PTK LIGANDS | SUGEN, INC. (US) | 2001-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020187978-A1 | 4-Heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors | CDK2, CDK20, CDK3 | KDM4E 1059/4885GAA 1878/4885HPGD 971/4885 |
| US-20250074920-A1 | MACROCYCLIC COMPOUNDS AND USE AS KINASE INHIBITORS | MAP3K20, MAP3K8, PRKACA | KDM4E 1460/4885GAA 1348/4885HPGD 2815/4885 |
| US-20230257396-A1 | MACROCYCLES AND THEIR USE | VHL, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, DLD | KDM4E 3077/4885GAA 520/4885HPGD 943/4885 |
| US-20020156292-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PDPK1, MAP3K20, PLK2 | KDM4E 1307/4885GAA 3447/4885HPGD 1053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.